Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

NIMBLE System The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents""""

Coordinator
Nimble Diagnostics SL, Spain
Runs
1 February 2024 to 31 July 2026
Status
Running
EU funding
€2.3m
Total cost
€3.3m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101145249

What the project is doing

In the project's own words, from its summary on CORDIS.

At NIMBLE Diagnostics we are developing a first-in-class microwave-based medical device for the non-invasive and non-ionizing monitoring of patients with implanted stents. Stents are one of the most implanted devices worldwide and are used to re-open blocked arteries and restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but, after implantation, become blocked or damaged in 30% of cases.

Symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence of serious complications, including strokes, heart attacks or sudden death. Diagnosis of malfunctioning stents is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex, costly and invasive procedure is not appropriate for ongoing monitoring, which is why the standard of care only reacts when patients already have potentially life-threatening symptoms.

The NIMBLE System can read the electromagnetic signature of any stent non-invasively in less than 5 seconds and can be used to provide information on stent status and malfunction during regular clinical visits. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of therapy, shifting from reactive to proactive care. Our technology is currently at TRL5/6, with an MVP that has shown excellent results in pre-clinical validations.

We have also started the first-in-human testing in a pilot study of 30 patients that will finish early 2024.The EIC Accelerator program will allow us to bridge the biggest risk of our project by performing the regulatory clinical trial to obtain the CE mark, as well as support us to create and access a multi-billion blue ocean market opportunity. This will allow us to establish NIMBLE as a European leader in the future of implant diagnostics and aid millions of patients worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Nimble Diagnostics SLBadalonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI